Sign in
TerminatedNo phase

Focused Power Ultrasound Mediated Inferior Perirenal Adipose Tissue Modification Therapy for Essential Hypertension

Key facts

Who runs it
The First Affiliated Hospital with Nanjing Medical University
Where
China3 sites in 1 countryChoose a country to see its sites
Trial code
Status
Terminated
People taking part
103 people enrolled
Started
1 Nov 2021
Ended
20 Nov 2023
Type of study
Interventional, 2 groupsOne group gets a sham (pretend) treatment, for comparison.
Treatments tested
  • focused power ultrasound mediate inferior perirenal adipose tussue modification
  • sham-control group
Record updated
7 December 2023
Why it stopped
Till interim analysis, 100 cases were enrolled, 71 of which during the COVID-19. Affected by epidemic control policy, 58 cases had examination window exceeded or missed, causing significant impact on endpoints, so we decided to terminate the trial.

Who can take part

Age
18 years to 65 years
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 20 criteriaShow less

Who can take part

  • Individual has office systolic blood pressure (SBP) ≥ 140 mmHg and <180 mmHg when receiving a medication regimen of one, two, or three antihypertensive medication classes;
  • Individual has 24-hour Ambulatory Blood Pressure Monitoring (ABPM) average SBP≥135 mmHg;
  • The anteroposterior, transverse and axial diameters of inferior perirenal fat pad measured by ultrasound should be at least 20mm;
  • Individual is willing to sign the informed consent of the study

Who cannot take part

  • Individual is diagnosed as secondary hypertension (e.g. renal parenchymal hypertension, renal artery stenosis, primary aldosteronism, pheochromocytoma, Cushing's syndrome, aortic coarctation, obstructive sleep apnea hypopnea syndrome);
  • Individual has history of kidney and or kidney surrounding tissue surgery
  • Individual has myocardial infarction, unstable angina pectoris, cerebrovascular accident or transient ischemic attack within 6 months of enrollment
  • Individual has type 1 diabetes or poorly-controlled type 2 diabetes;
  • Individual has severe structural heart disease (e.g. heart valve disease, cardiomyopathy, congenital heart disease)
  • Individual has infected waist skin
  • Individual has malignant tumor
  • Individuals has impairment of liver or kidney function (ALT, AST or creatinine is greater than 2 times of the upper limit of normal reference)
  • Individual has uncontrolled thyroid dysfunction
  • Individual has urinary calculi and/or hematuria;
  • Individual has atrial fibrillation
  • Individual has second degree and above atrioventricular block;
  • Individual has abnormal coagulation function
  • Individual is pregnant, nursing or planning to be pregnant
  • Individual is unwilling to sign informed consent
  • Individual fails to complete the screening period

Where is this trial?

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

This randomized, double blinded, sham-control trial aims to evaluate the efficacy and safety of a novel focused power ultrasound mediated inferior perirenal adipose tissue modification therapy for essential hypertension.

The 2 groups in the trial

  • intervention groupTreatment being tested

    In intervention group, participants will receive the whole peri-renal fat modification therapy (including peri-renal fat ultrasonic measurement and localization,focused ultrasound treatment parameters setting and initiating)

    Treatment: focused power ultrasound mediate inferior perirenal adipose tussue modification

  • sham-control groupSham treatment, for comparison

    In sham control group, participants will receive the sham control therapy(including peri-renal fat ultrasonic measurement and localization,focused ultrasound treatment parameters setting),however,without initiating the focused ultrasound equipment.

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Focused Power Ultrasound Mediated Inferior Perirenal Adipose Tissue Modification Therapy for Essential Hypertension: a Multicenter, Randomized, Double-blinded Controlled Trial. PARADISE Study
Publications
Record updated
7 December 2023